Edison - an Investment Research Company - has published an update in the coverage of Oncology Venture’s share
If you are interested in following the Edison coverage of the Oncology Venture share – sign up here: link For further information about Oncology Venture, please contact: Ulla Hald Buhl, COO and Chief IR & or Peter Buhl Jensen, CEOMobile: +45 21 60CommunicationsMobile: +45 2170 89 22E-mail: pbj@oncologyventure.com 1049uhb@oncologyventure.com About Oncology Venture Sweden AB Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture